YCT-529, a hormone-free oral contraceptive, has concluded its first safety trial in humans, signaling progress in male contraceptive options. This daily pill temporarily stops sperm production by blocking a vitamin A metabolite from binding to its receptor in the testes. This mechanism prevents the necessary gene-expression changes that initiate sperm production. While the trial confirmed safety, it did not assess the contraceptive's efficacy, which is being studied in ongoing trials. Experts emphasize the increasing need for reversible male contraceptive methods.
The daily pill, called YCT-529, blocks a vitamin A metabolite from binding to its receptor in the testes; this prevents the chain of gene-expression changes that are required to start the sperm-making process.
Safety results from the early phase 1 clinical trial were published on Tuesday in Communications Medicine. The trial did not assess the pill's efficacy in reducing sperm, and the drug's developer, YourChoice Therapeutics, is currently running trials to collect that data.
We really need more reversible contraceptive methods for men, she says.
A hormone-free pill, called YCT-529, that temporarily stops sperm production by blocking a vitamin A metabolite has just concluded its first safety trial in humans.
Collection
[
|
...
]